WILMINGTON, MASSACHUSETTS--(Marketwire - October 30, 2007) - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, today announced that it has entered into definitive agreements with institutional investors with respect to the private placement of 4,581,043 shares of its common stock at $2.40 per share. The transaction also includes warrants to purchase up to 1,145,259 shares of DUSA's common stock at an exercise price of $2.85 per share. The warrants will expire on April 30, 2013. Investors in this transaction include Deerfield Management and Greenway Capital.
